XNYS
DHR
Market cap152bUSD
Oct 08, Last price
217.46USD
1D
-0.47%
1Q
9.25%
Jan 2017
179.37%
Name
Danaher Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Related entities
Subsidiaries (8)
CEPHEID INDIA PRIVATE LIMITED
DH EUROPE FINANCE II S.À R.L.
DHR HOLDING INDIA PRIVATE LIMITED
LEICA Mikrosysteme GmbH
RADIOMETER MEDICAL ApS
BECKMAN COULTER INDIA PRIVATE LIMITED
HemoCue Aktiebolag
VIDEOJET TECHNOLOGIES (I) PRIVATE LIMITED
Key people
Steven Rales
Chairman of the Board · since 1990
Rainer Blair
President, Chief Executive Officer, Director · since 2020
Matthew Gugino
Group Chief Financial Officer · since 2026
Gregory Milosevich
Executive Vice President · since 2025
Christopher Riley
Executive Vice President · since 2024
Julie Sawyer Montgomery
Executive Vice President · since 2024
R. Bradley Gray
Senior Vice President - Strategic Development · since 2024
Jose-Carlos Gutierrez-Ramos
Senior Vice President, Chief Science Officer · since 2020
Daniel Raskas
Senior Vice President - Corporate Development · since 2010
Martin Stumpe
Chief Technology Officer and AI Officer · since 2025
Senior Vice President, General Counsel · since 2016
Georgeann Couchara
Senior Vice President - Human Resources · since 2022
Linda Hefner Filler
Lead Independent Director · since 2020
Director · since 1990
Feroz Dewan
Independent Director · since 2022
Charles Lamanna
Independent Director · since 2025
Independent Director · since 2011
Independent Director · since 2019
Independent Director · since 2021
John Schwieters
Independent Director · since 2003
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
2200 Pennsylvania Avenue North West
Suite 800W
Washington, DC 20037-1731
US
Suite 800W
Washington, DC 20037-1731
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||